Cost-Minimization Analyses of Adalimumab Compared with Selective Immunosuppressive Cytokines Blockers and Inhibitors of Tumor Necrosis Factor Alpha Indicated for the Treatment of Rheumatoid Arthritis, Psoriasis and Crohn’s Disease in the Private Market in Mexico

Autor:	JL Sánchez-Casillas, JC Pozos-Espíndola, CA Pichardo-Piña
Rok vydání:	2015
Předmět:	Oncology medicine.medical_specialty Crohn's disease business.industry Health Policy Private market Public Health Environmental and Occupational Health medicine.disease Text mining Psoriasis Rheumatoid arthritis Internal medicine Adalimumab Medicine Tumor necrosis factor alpha business medicine.drug
Zdroj:	Value in Health. 18(7)
ISSN:	1098-3015
DOI:	10.1016/j.jval.2015.09.387
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76d70554d1b3f3fe3e145117cdbe5db7 Zobrazit plný text záznamu Full Text from ScienceDirect